Investor Relations Investor Center Stock Information Financial Information Corporate Governance Press Releases Events & Presentations Investor FAQ Contact Us
Press Releases Year: - Any -202420232022202120202019201820172016201520142013201220112010200920082007 Summary ToggleProof of RNAi in Man Strengthens Leadership Position of Tekmira's LNP Delivery Technology Jan 10, 2011 ... Read more Summary ToggleTekmira Initiates TKM-PLK1 Phase 1 Human Clinical Trial Dec 22, 2010 Tekmira Initiates TKM-PLK1 Phase 1 Human Clinical Trial 18 KB ... Read more Summary ToggleTekmira Pharmaceuticals to Webcast Presentation at the Piper Jaffray Health Care Conference Nov 24, 2010 Tekmira Pharmaceuticals to Webcast Presentation at the Piper Jaffray Health Care Conference 12.1 KB ... Read more Summary ToggleTekmira Intellectual Property Portfolio Expands with Granting of Key Patents Covering LNP Manufacturing and Mitigation of siRNA Immune Stimulation Nov 22, 2010 Tekmira Intellectual Property Portfolio Expands with Granting of Key Patents Covering LNP Manufacturing and Mitigation of siRNA Immune Stimulation 17.8 KB ... Read more Summary ToggleTekmira Pharmaceuticals Comments on Roche Restructuring Nov 17, 2010 Tekmira Pharmaceuticals Comments on Roche Restructuring 18.1 KB ... Read more Summary ToggleTekmira Pharmaceuticals to Commence Trading on the NASDAQ Capital Market under Symbol "TKMR" Nov 15, 2010 Tekmira Pharmaceuticals to Commence Trading on the NASDAQ Capital Market under Symbol "TKMR" 17.1 KB ... Read more Summary ToggleTekmira Pharmaceuticals Announces Third Quarter 2010 Financial Results Nov 15, 2010 Tekmira Pharmaceuticals Announces Third Quarter 2010 Financial Results 17.1 KB ... Read more Summary ToggleTekmira Partner Alnylam Presents Additional ALN-VSP Interim Phase 1 Clinical Trial Data at the Chemotherapy Foundation Symposium Nov 10, 2010 Tekmira Partner Alnylam Presents Additional ALN-VSP Interim Phase 1 Clinical Trial Data at the Chemotherapy Foundation Symposium 19 KB ... Read more Summary ToggleTekmira Pharmaceuticals Conference Call Advisory Third Quarter 2010 Operating Results and Corporate Update Nov 08, 2010 ... Read more Summary ToggleAlnylam Grants New InterfeRxTM Intellectual Property License to Tekmira for Development and Commercialization of TKM-Ebola, an RNAi Therapeutic for the Treatment of Ebola Virus Infection Nov 04, 2010 Alnylam Grants New InterfeRxTM Intellectual Property License to Tekmira for Development and Commercialization of TKM-Ebola, an RNAi Therapeutic for the Treatment of Ebola Virus Infection 23.4 KB ... Read more Pagination First page First Previous page Previous … Page 43 Current page 44 Page 45 Page 46 … Next page Next Last page Last Shareholder Tools Email Alerts Email Alerts RSS News Feeds RSS News Feeds Download Library Download Library
Press Releases Year: - Any -202420232022202120202019201820172016201520142013201220112010200920082007 Summary ToggleProof of RNAi in Man Strengthens Leadership Position of Tekmira's LNP Delivery Technology Jan 10, 2011 ... Read more Summary ToggleTekmira Initiates TKM-PLK1 Phase 1 Human Clinical Trial Dec 22, 2010 Tekmira Initiates TKM-PLK1 Phase 1 Human Clinical Trial 18 KB ... Read more Summary ToggleTekmira Pharmaceuticals to Webcast Presentation at the Piper Jaffray Health Care Conference Nov 24, 2010 Tekmira Pharmaceuticals to Webcast Presentation at the Piper Jaffray Health Care Conference 12.1 KB ... Read more Summary ToggleTekmira Intellectual Property Portfolio Expands with Granting of Key Patents Covering LNP Manufacturing and Mitigation of siRNA Immune Stimulation Nov 22, 2010 Tekmira Intellectual Property Portfolio Expands with Granting of Key Patents Covering LNP Manufacturing and Mitigation of siRNA Immune Stimulation 17.8 KB ... Read more Summary ToggleTekmira Pharmaceuticals Comments on Roche Restructuring Nov 17, 2010 Tekmira Pharmaceuticals Comments on Roche Restructuring 18.1 KB ... Read more Summary ToggleTekmira Pharmaceuticals to Commence Trading on the NASDAQ Capital Market under Symbol "TKMR" Nov 15, 2010 Tekmira Pharmaceuticals to Commence Trading on the NASDAQ Capital Market under Symbol "TKMR" 17.1 KB ... Read more Summary ToggleTekmira Pharmaceuticals Announces Third Quarter 2010 Financial Results Nov 15, 2010 Tekmira Pharmaceuticals Announces Third Quarter 2010 Financial Results 17.1 KB ... Read more Summary ToggleTekmira Partner Alnylam Presents Additional ALN-VSP Interim Phase 1 Clinical Trial Data at the Chemotherapy Foundation Symposium Nov 10, 2010 Tekmira Partner Alnylam Presents Additional ALN-VSP Interim Phase 1 Clinical Trial Data at the Chemotherapy Foundation Symposium 19 KB ... Read more Summary ToggleTekmira Pharmaceuticals Conference Call Advisory Third Quarter 2010 Operating Results and Corporate Update Nov 08, 2010 ... Read more Summary ToggleAlnylam Grants New InterfeRxTM Intellectual Property License to Tekmira for Development and Commercialization of TKM-Ebola, an RNAi Therapeutic for the Treatment of Ebola Virus Infection Nov 04, 2010 Alnylam Grants New InterfeRxTM Intellectual Property License to Tekmira for Development and Commercialization of TKM-Ebola, an RNAi Therapeutic for the Treatment of Ebola Virus Infection 23.4 KB ... Read more Pagination First page First Previous page Previous … Page 43 Current page 44 Page 45 Page 46 … Next page Next Last page Last
Tekmira Intellectual Property Portfolio Expands with Granting of Key Patents Covering LNP Manufacturing and Mitigation of siRNA Immune Stimulation 17.8 KB
Tekmira Partner Alnylam Presents Additional ALN-VSP Interim Phase 1 Clinical Trial Data at the Chemotherapy Foundation Symposium 19 KB
Alnylam Grants New InterfeRxTM Intellectual Property License to Tekmira for Development and Commercialization of TKM-Ebola, an RNAi Therapeutic for the Treatment of Ebola Virus Infection 23.4 KB
